多发性硬化和COVID-19:一个双向的门德尔式随机化研究.
Shitong Liu1, Yixin Liang2, Binbin Sheng1,3
1School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.
Frontiers in immunology
|November 4, 2024
概括
遗传因素影响COVID-19在多发性硬化症 (MS) 患者的结果. SNP rs10191329可能会降低严重的COVID-19风险,而干扰素β治疗可能会提供保护.
科学领域:
- 免疫遗传学 免疫遗传学
- 神经学 神经学
- 传染性疾病 传染性疾病
背景情况:
- 多发性硬化症 (MS) 是一种影响中枢神经系统的自身免疫性疾病.
- 多发性硬化症对COVID-19结果的影响和遗传因素的作用需要进一步调查.
- 干扰素β (IFNβ) 是MS的常见治疗方法.
研究的目的:
- 使用孟德尔随机化研究MS和COVID-19结果之间的关系.
- 评估遗传因素,特别是SNP rs10191329对MS患者COVID-19易感性和严重性的影响.
- 评估IFNβ治疗对MS患者COVID-19结局的影响.
主要方法:
- 门德尔的随机化分析利用全基因组关联研究总结统计.
- 单核酸多态 (SNP) 的选择与MS强烈相关.
- 检查选择的SNP和IFNβ治疗对三种COVID-19结局的影响:SARS-CoV-2感染,住院COVID-19和严重COVID-19.
主要成果:
- 观察到MS和COVID-19风险增加之间的潜在关联.
- 患有rs10191329 SNP的个体显示,患重症COVID-19的可能性降低.
- 在接受治疗的与未接受治疗的MS患者中,IFNβ治疗和COVID-19结果之间没有发现显著的因果关系,这表明IFNβ的潜在保护作用.
结论:
- 遗传因素,如rs10191329,在调节MS患者的COVID-19结果方面发挥着作用.
- 在患有MS的个体中,IFNβ治疗可能会对SARS-CoV-2感染产生保护作用.
- 考虑到遗传倾向的个性化治疗策略对于在COVID-19大流行期间管理MS患者至关重要.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...


